Additionally, this vaccine increased higher CD8+ T-cell responses towards subdominant antigens and increased antibody responses towards cancer cells expressing the native Syncytin-1 protein compared to the corresponding fusion-competent vaccine. The gene discussed is ERVW-1; the disease is cancer.